HAYWARD, Calif., March 23, 2015 /PRNewswire/ -- Anthera
Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it
has completed the previously announced underwritten public offering
of 5,555,556 shares of its common stock, offered at a price of
$4.50 per share. In addition,
Anthera has granted the underwriters a 30-day option to purchase up
to an additional 833,333 shares of common stock to cover
over-allotments, if any. The gross proceeds to the Company
from the sale of shares in this offering, before deducting
customary underwriting discounts and commissions, were
approximately $25,000,000
million. Anthera intends to use the net proceeds from
this offering for clinical research and development and general
corporate purposes.
Piper Jaffray & Co. has acted
as sole underwriter in the offering. The Trout Group, LLC has acted
as advisor to the Company.
The securities described above were offered by the Company
pursuant to a shelf registration statement previously filed with,
and declared effective by, the Securities and Exchange Commission
(the "SEC"). A final prospectus supplement and accompanying
prospectus relating to the offering has been filed with the SEC and
is available on the SEC's website at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from
Piper Jaffray & Co., Attention:
Prospectus Department, at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at
800-747-3924 or by email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or jurisdiction.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused
on advancing the development and commercialization of innovative
medicines that benefit patients with unmet medical needs.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include statements about
Anthera's expectations with respect to its public offering,
including statements about its intended use of proceeds from
the offering. Such statements are based on Anthera's
expectations as of the date of this press release and are subject
to certain risks and uncertainties that could cause actual results
to differ materially, including but not limited to those set forth
in Anthera's public filings with the SEC, including Anthera's
Annual Report on Form 10-K for the year ended December 31, 2014. Anthera disclaims
any intent or obligation to update any forward-looking statements,
whether because of new information, future events or otherwise,
except as required by applicable law.
CONTACT: Dennis Lutz of Anthera
Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/anthera-pharmaceuticals-announces-completion-of-public-offering-of-common-stock-300054545.html
SOURCE Anthera Pharmaceuticals, Inc.